Floatz logo

Safinamide

Dyskinesia, Drug-Induced

Zambon SpASmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Dyskinesia, Drug-Induced cohort.

Asset / SponsorPhaseRating
MT-5199
Neurocrine Biosciences
Phase 4BBB
Ginkgo Biloba
Beijing HuiLongGuan Hospital
Phase 3BB
Varenicline Tartrate
Corporal Michael J. Crescenz VA Medical Center
Phase 4B
Vitamin B6
Beersheva Mental Health Center
Phase 3B
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2B

View all 14 →

Same molecule, other indications

Safinamide is also rated in:

Parkinson diseaseDormant
A
Indicative ·
83 / 100
View asset →
Parkinson diseaseDormant
BBB
Indicative ·
73 / 100
View asset →
kidney failureDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →